Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

• Published in: Molecular therapy Vol. 18; no. 7; pp. 1318 - 1329
• Main Authors: Haurigot, Virginia, Mingozzi, Federico, Buchlis, George, Hui, Daniel J, Chen, Yifeng, Basner-Tschakarjan, Etiena, Arruda, Valder R, Radu, Antoneta, Franck, Helen G, Wright, J Fraser, Zhou, Shangzhen, Stedman, Hansell H, Bellinger, Dwight A, Nichols, Timothy C, High, Katherine A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2010; Elsevier Limited; Nature Publishing Group
• Subjects: Animals; Antibodies; Antigens; CD4-Positive T-Lymphocytes - metabolism; Cell Line; Cytokines; Dependovirus - genetics; Disease; Dogs; Drug dosages; Enzymes; Factor IX - genetics; Factor IX - metabolism; Flow Cytometry; Genetic Vectors - adverse effects; Genetic Vectors - genetics; Hemophilia; Hemophilia B - metabolism; Hemophilia B - therapy; Hospitals; Humans; Immunoglobulin G - metabolism; Interferon-gamma - metabolism; Interleukin-10 - metabolism; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Original; Peptides; United States > US; Pennsylvania
• ISSN: 1525-0016; 1525-0024; 1525-0024
• DOI: 10.1038/mt.2010.73

Muscle represents an attractive target tissue for adeno-associated virus (AAV) vector–mediated gene transfer for hemophilia B (HB). Experience with direct intramuscular (i.m.) administration of AAV vectors in humans showed that the approach is safe but fails to achieve therapeutic efficacy. Here, we present a careful evaluation of the safety profile (vector, transgene, and administration procedure) of peripheral transvenular administration of AAV-canine factor IX (cFIX) vectors to the muscle of HB dogs. Vector administration resulted in sustained therapeutic levels of cFIX expression. Although all animals developed a robust antibody response to the AAV capsid, no T-cell responses to the capsid antigen were detected by interferon (IFN)-γ enzyme-linked immunosorbent spot (ELISpot). Interleukin (IL)-10 ELISpot screening of lymphocytes showed reactivity to cFIX-derived peptides, and restimulation of T cells in vitro in the presence of the identified cFIX epitopes resulted in the expansion of CD4+FoxP3+IL-10+ T-cells. Vector administration was not associated with systemic inflammation, and vector spread to nontarget tissues was minimal. At the local level, limited levels of cell infiltrates were detected when the vector was administered intravascularly. In summary, this study in a large animal model of HB demonstrates that therapeutic levels of gene transfer can be safely achieved using a novel route of intravascular gene transfer to muscle.